Novel Therapies for Pancreatic Adenocarcinoma

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2004 Jun 12

PMID 15191689

Citations 7

Authors

Simona M Pino

Henry Q Xiong

David McConkey

James L Abbruzzese

Affiliations

Soon will be listed here.

Abstract

Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. In this article we review the current status of investigations into several classes of agents: matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; epidermal growth factor receptor inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors; cyclooxygenase-2 inhibitors, and others. The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed.

Citing Articles

Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.

Takahashi M, Mutoh M, Ishigamori R, Fujii G, Imai T Semin Immunopathol. 2012; 35(2):203-27.

PMID: 22955327 DOI: 10.1007/s00281-012-0340-x.

Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells.

Chang Z, Wei J, Qin C, Hao K, Tian X, Xie K Dig Dis Sci. 2012; 57(5):1181-9.

PMID: 22271412 DOI: 10.1007/s10620-012-2036-4.

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.

Bafna S, Kaur S, Momi N, Batra S Br J Cancer. 2009; 101(7):1155-61.

PMID: 19738614 PMC: 2768097. DOI: 10.1038/sj.bjc.6605285.

siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.

Liu W, Yan H, Qin R, Tian R, Wang M, Jiang J Dig Dis Sci. 2008; 54(1):89-96.

PMID: 18594980 DOI: 10.1007/s10620-008-0329-4.

Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer.

Yan B, Dam J Can J Gastroenterol. 2008; 22(4):405-10.

PMID: 18414717 PMC: 2662900. DOI: 10.1155/2008/104398.

References

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M . Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1):5-26. DOI: 10.3322/canjclin.53.1.5. View

Hess K, Abbruzzese J . Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol. 2001; 19(15):3445-6. DOI: 10.1200/JCO.2001.19.15.3445. View

Koong A, Mehta V, Le Q, Fisher G, Terris D, Brown J . Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000; 48(4):919-22. DOI: 10.1016/s0360-3016(00)00803-8. View

Leahy K, Ornberg R, Wang Y, Zweifel B, Koki A, Masferrer J . Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002; 62(3):625-31. View

Bruns C, Harbison M, Davis D, Portera C, Tsan R, McConkey D . Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000; 6(5):1936-48. View

Chen F, Castranova V, Shi X . New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001; 159(2):387-97. PMC: 1850555. DOI: 10.1016/s0002-9440(10)61708-7. View

Yip-Schneider M, Sweeney C, Jung S, Crowell P, Marshall M . Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001; 298(3):976-85. View

Watson S, Michaeli D, Grimes S, Morris T, Robinson G, Varro A . Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 1996; 56(4):880-5. View

Mendelsohn J . Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000; 6(3):747-53. View

10.

Goetze J, Nielsen F, Burcharth F, Rehfeld J . Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer. 2000; 88(11):2487-94. DOI: 10.1002/1097-0142(20000601)88:11<2487::aid-cncr9>3.0.co;2-e. View

11.

Bramhall S, Schulz J, Nemunaitis J, Brown P, Baillet M, Buckels J . A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002; 87(2):161-7. PMC: 2376102. DOI: 10.1038/sj.bjc.6600446. View

12.

Crooke S . Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev. 1996; 6(2):145-7. DOI: 10.1089/oli.1.1996.6.145. View

13.

Neoptolemos J, Dunn J, Stocken D, Almond J, Link K, Beger H . Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358(9293):1576-85. DOI: 10.1016/s0140-6736(01)06651-x. View

14.

Cohen S, Ho L, Ranganathan S, Abbruzzese J, Alpaugh R, Beard M . Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003; 21(7):1301-6. DOI: 10.1200/JCO.2003.08.040. View

15.

Arteaga C . Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002; 29(5 Suppl 14):3-9. DOI: 10.1053/sonc.2002.35642. View

16.

Chen G, Oh S, Monia B, Stacey D . Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996; 271(45):28259-65. DOI: 10.1074/jbc.271.45.28259. View

17.

Yip-Schneider M, Barnard D, Billings S, Cheng L, Heilman D, Lin A . Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000; 21(2):139-46. DOI: 10.1093/carcin/21.2.139. View

18.

Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E . A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994; 370(6484):61-5. DOI: 10.1038/370061a0. View

19.

Casey P, Solski P, Der C, Buss J . p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A. 1989; 86(21):8323-7. PMC: 298273. DOI: 10.1073/pnas.86.21.8323. View

20.

Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maillet B . Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer. 1994; 69(1):144-51. PMC: 1968784. DOI: 10.1038/bjc.1994.24. View